Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Accumulated Expenses: 2012-2024

Historic Accumulated Expenses for Ptc Therapeutics (PTCT) over the last 10 years, with Dec 2024 value amounting to $61.6 million.

  • Ptc Therapeutics' Accumulated Expenses rose 7.05% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year increase of 7.05%. This contributed to the annual value of $61.6 million for FY2024, which is 16.92% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Accumulated Expenses of $61.6 million as of FY2024, which was down 16.92% from $74.1 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Accumulated Expenses ranged from a high of $74.1 million in FY2023 and a low of $53.3 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $66.1 million, with a median of $62.7 million in 2022.
  • Per our database at Business Quant, Ptc Therapeutics' Accumulated Expenses soared by 38.81% in 2020 and then declined by 16.92% in 2024.
  • Ptc Therapeutics' Accumulated Expenses (Yearly) stood at $53.3 million in 2020, then increased by 4.58% to $55.7 million in 2021, then rose by 12.45% to $62.7 million in 2022, then climbed by 18.26% to $74.1 million in 2023, then fell by 16.92% to $61.6 million in 2024.